Full-Length SMN Transcript in Extracellular Vesicles as Biomarker in Individuals with Spinal Muscular Atrophy Type 2 Treated with Nusinersen

被引:6
|
作者
Trifunov, Selena [1 ,6 ]
Natera-de Benito, Daniel [1 ,2 ]
Carrera-Garcia, Laura [1 ,2 ]
Codina, Anna [1 ]
Exposito-Escudero, Jesica [1 ,2 ]
Ortez, Carlos [1 ]
Medina, Julita [4 ]
Torres Alcala, Soraya [3 ]
Bernal, Sara [5 ,6 ]
Alias, Laura [5 ,6 ]
Badosa, Carmen [1 ]
Balsells, Sol [7 ]
Alcolea, Daniel [3 ]
Nascimento, Andres [1 ,2 ,6 ]
Jimenez-Mallebrera, Cecilia [1 ,6 ,8 ]
机构
[1] Inst Recerca St Joan De Deu, Appl Res Neuromuscular Dis, Barcelona, Spain
[2] Hosp San Juan Dios, Dept Neurol, Neuromuscular Unit, Barcelona, Spain
[3] Univ Autonoma Barcelona, Inst Invest Biomed St Pau Hosp St Pau, Hosp Santa Creu & St Pau, Dept Neurol, Barcelona, Spain
[4] Hosp St Joan De Deu, Rehabil & Phys Unit Dept, Barcelona, Spain
[5] Univ Autonoma Barcelona, Inst Invest Biomed St Pau Hosp St Pau, Dept Genet, Barcelona, Spain
[6] Inst Salud Carlos III, Biomed Network Res Ctr Rare Dis CIBERER, Madrid, Spain
[7] Inst Recerca St Joan De Deu, Stat Dept, Barcelona, Spain
[8] Univ Barcelona, Dept Genet Microbiol & Stat, Barcelona, Spain
关键词
Biomarkers; cerebrospinal fluid; nusinersen; response predictors; serum; spinal muscular atrophy; SHAM CONTROL; EXPRESSION; EXOSOMES;
D O I
10.3233/JND-230012
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: Three therapeutic strategies have radically changed the therapeutic scenario for spinal muscular atrophy (SMA). However, therapeutic response differs between individuals. There is a need to identify biomarkers to further assess therapeutic response and to better understand which variables determine the extent of response. Methods: We conducted a study using an optimized digital droplet PCR-based method for the ultra-sensitive detection of SMN transcript in serum EVs from SMA 2 individuals treated with nusinersen over 14 months. In parallel, we investigated levels of serum and CSF neurofilament heavy chain (pNF-H) in the same cohort. Results: Expression of flSMN transcript in EVs of SMA 2 individuals prior to nusinersen was lower than in controls (0.40 vs 2.79 copies/ul; p < 0.05) and increased after 14 months of nusinersen (0.40 vs 1.11 copies/ul; p < 0.05). The increase in flSMN with nusinersen was significantly higher in younger individuals (p < 0.05). Serum pNF-h was higher in non-treated individuals with SMA 2 than in controls (230.72 vs 22.88 pg/ml; p < 0.05) and decreased with nusinersen (45.72 pg/ml at 6 months, 39.02 pg/ml at 14 months). CSF pNF-h in SMA 2 individuals also decreased with nusinersen (248.04 pg/ml prior to treatment, 197.10 pg/dl at 2 months, 104.43 pg/dl at 6 months, 131.03 pg/dl at 14 months). Conclusions: We identified an increase of flSMN transcript in serum EVs of SMA 2 individuals treated with nusinersen that was more pronounced in the younger individuals. Our results indicate that flSMN transcript expression in serum EVs is a possible biomarker in SMA to predict or monitor the response to treatment.
引用
收藏
页码:653 / 665
页数:13
相关论文
共 50 条
  • [1] Evaluation of Mean Percentage of Full-Length SMN Transcripts as a Molecular Biomarker of Spinal Muscular Atrophy
    Maretina, Marianna
    Egorova, Anna
    Lanko, Kristina
    Baranov, Vladislav
    Kiselev, Anton
    GENES, 2022, 13 (10)
  • [2] Exclusion of Htra2-β1, an up-regulator of full-length SMN2 transcript, as a modifying gene for spinal muscular atrophy
    Helmken, C
    Wirth, B
    HUMAN GENETICS, 2000, 107 (06) : 554 - 558
  • [3] Exclusion of Htra2-β1, an up-regulator of full-length SMN2 transcript, as a modifying gene for spinal muscular atrophy
    Claudia Helmken
    Brunhilde Wirth
    Human Genetics, 2000, 107 : 554 - 558
  • [4] Sitting in patients with spinal muscular atrophy type 1 treated with nusinersen
    Aragon-Gawinska, Karolina
    Daron, Aurore
    Ulinici, Ana
    Vanden Brande, Laura
    Seferian, Andreea
    Gidaro, Teresa
    Scoto, Mariacristina
    Deconinck, Nicolas
    Servais, Laurent
    Benezit, Audrey
    Mathieu, Marie-Laure
    Cances, Claude
    Durigneux, Julien
    Ropars, Juliette
    Chouchane, Mondher
    Forey, Peggy
    Lazaro, Leila
    Hughes, Imelda
    Illingworth, Marjorie
    Marini-Bettolo, Chiara
    Cuppen, Inge
    Modrzejewska, Sandra
    Balintova, Zdenka
    Haberlova, Jana
    Drimtzia, Kate
    Blaschek, Astrid
    Ambegankoar, Gautam
    Annoussamy, Melanie
    DEVELOPMENTAL MEDICINE AND CHILD NEUROLOGY, 2020, 62 (03): : 310 - 314
  • [5] Spinal muscular atrophy type II skeletal muscle treated with Nusinersen and Risdiplam shows SMN restoration but mitochondrial deficiency
    Grandi, F.
    Astord, S.
    Pezet, S.
    Gidaja, E.
    Mazzucchi, S.
    Chapart, M.
    Vasseur, S.
    Mamchaoui, K.
    Smeriglio, P.
    NEUROMUSCULAR DISORDERS, 2024, 43
  • [6] SMNΔ7, the major product of the centromeric survival motor neuron (SMN2) gene, extends survival in mice with spinal muscular atrophy and associates with full-length SMN
    Le, TT
    Pham, LT
    Butchbach, MER
    Zhang, HL
    Monani, UR
    Coovert, DD
    Gavrilina, TO
    Xing, L
    Bassell, GJ
    Burghes, AHM
    HUMAN MOLECULAR GENETICS, 2005, 14 (06) : 845 - 857
  • [7] Cathepsin D as biomarker in CSF of nusinersen-treated patients with spinal muscular atrophy
    Schorling, D.
    Koelbel, H.
    Hentschel, A.
    Pechmann, A.
    Meyer, N.
    Wirth, B.
    Rombo, R.
    Sickmann, A.
    Kirschner, J.
    Schara-Schmidt, U.
    Lochmueller, H.
    Roos, A.
    NEUROMUSCULAR DISORDERS, 2022, 32 : S64 - S64
  • [8] Evaluation of the neurofilament light chain as a biomarker in children with spinal muscular atrophy treated with nusinersen
    Lee, Y.
    Kim, S.
    Byun, J.
    Lee, H.
    Yun, J.
    Kwon, S.
    NEUROMUSCULAR DISORDERS, 2023, 33 : S163 - S163
  • [9] Evaluation of the neurofilament light chain as a biomarker in children with spinal muscular atrophy treated with nusinersen
    Seo, Gigyo
    Kim, Saeyoon
    Byun, Jun Chul
    Kwon, Soonhak
    Lee, Yun Jeong
    BRAIN & DEVELOPMENT, 2023, 45 (10): : 554 - 563
  • [10] Evolution of bulbar function in spinal muscular atrophy type 1 treated with nusinersen
    Weststrate, Harriet
    Stimpson, Georgia
    Thomas, Lily
    Scoto, Mariacristina
    Johnson, Emily
    Stewart, Alexandra
    Muntoni, Francesco
    Baranello, Giovanni
    Conway, Eleanor
    DEVELOPMENTAL MEDICINE AND CHILD NEUROLOGY, 2022, 64 (07): : 907 - 914